Enfektif Endokarditli Bir Olguda Seftriakson Tedavisine Bağlı Safra Kesesinde Çoklu Taş Oluşumu

Öz

Seftriakson, safra kesesinde geri dönüşümlü çöküntülere yol açtığı bilinen bir üçüncü kuşak sefalosporindir. Oluşturduğu bu çöküntüler biliyer pseudolithiasis olarak adlandırılır. Bu yazıda, enfektif endokardit tanısıyla seftriakson kullanılan 6 yaşında bir olgu sunulmuştur. Hastada karın ağrısı nedeniyle yapılan ultrasonografik incelemede safra kesesinde çoklu taşlar gözlenmiş ve seftriakson tedavisinin kesilmesiyle semptomlar kaybolmuş ve safra kesesindeki taşların sayı ve büyüklüğünde belirgin derecede azalma gözlenmiştir. Çocukluklarda sıklıkla kullanılan seftriakson tedavisi sırasında safra taşlarının gelişebileceği ve bu taşların cerrahi tedavi gerekmeden kendiliğinden gerileyebileceği vurgulanmıştır.

Anahtar Kelimeler

• İnfektif endokardit, Kolelitiyazis, Seftriakson

Multiple Gallstone Formation due to Ceftriaxone Treatment in a Child Diagnosed with Infective Endocarditis

Öz

Ceftriaxone, a third-generation cephalosporin, has been known to cause reversible sludge in the gallbladder. This sludge is referred to as biliary pseudolithiasis. In this article, a six-year-old child diagnosed with infective endocarditis is presented. He suffered from abdominal pain during the treatment with ceftriaxone and we performed an abdominal ultrasonographic examination that revealed multiple stones in the gallbladder. His symptoms quickly disappeared after the cessation of the treatment with ceftriaxone and we observed a significant decrease in size and number of the gallstones. Ceftriaxone is a commonly used drug in childhood and may cause gallstone formation. These gallstones usually resolve spontaneously and do not necessitate any surgical procedure

Anahtar Kelimeler

• Infective endocarditis, Cholelithiasis, Ceftriaxone

Kaynakça

1. Herzog D, Bouchard G. High rate of complicated idiopathic gallstone disease in pediatric patients of a North American tertiary care center. World J Gastroenterol 2008;14:1544-8.
2. Wesdorp I, Bosman D, de Graaff A, Aronson D, van der Blij F, Taminiau J. Clinical presentations and predisposing factors of cholelithiasis and sludge in children. J Pediatr Gastroenterol Nutr 2000;31:411–7.
3. Lobe TE. Cholelithiasis and cholecystitis in children. Semin Pediatr Surg 2000;9:170–6.
4. Tannuri A, Leal A, Velhote M, Gonlçalves M, Tannuri U. Management of gallstone disease in children: A new protocol based on the experience of a single center. J Pediatr Surg 2012;47:2033–8.
5. Bogue CO, Murphy AJ, Gerstle JT, Moineddin R, Daneman A. Risk factors, complications, and outcomes of gallstones in children: A single-center review. J Pediatr Gastroenterol Nutr 2010;50:303-8.
6. Mehta S, Lopez ME, Chumpitazi BP, Mazziotti MV, Brandt ML, Fishman DS. Clinical characteristics and risk factors for symptomatic pediatric gallbladder disease. Pediatrics 2012;129:82-8.
7. Kong MS, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi 1996;19:50-4.
8. Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 1984;27:429-527.

9. Arvidsson A, Alvan G, Angelin B, Borga O, Nord CE. Ceftriaxone. Renal and biliary excretion and effect on colon microflora. J Antimicrob Chemother 1982;14:207–15.
10. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology 1991;100:1665–70.
11. Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis 1986;5:708–10.
12. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988;2:1411–3.
13. De Moor RA, Egberts AC, Schröder CH. Ceftriaxone associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999;158:975–7.
14. Cochat P, Cochat N, Jouvenet M, Floret D, Wright C, Martin X, et al. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant 1990;5:974–6.
15. Shiina Y, Toyoda T, Kawasoe Y, Tateno S, Shirai T, Matsuo K, et al. The prevalence and risk factors for cholelithiasis and asymptomatic gallstones in adults with congenital heart disease. Int J Cardiol 2011;152:171–6.
16. Bonnet JP, Abid L, Dabhar A, L´evy A, Soulier Y, Blangy S. Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: A prospective study in 34 children. Eur J Pediatr Surg 2000;10:368–71.
17. Fretzayas A, Liapi O, Papadopoulou A, Nicolaidou P, Stamoulakatou A. Is Ceftriaxone-Induced biliary pseudolithiasis influenced by UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms? Case Rep Med 2011;2011:730250.
18. Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone- associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772–8.
19. Kim YS, Kestell MF, Lee SP. Gall-bladder sludge: Lessons from ceftriaxone. J Gastroenterol Hepatol 1992;7:618-21.